CANCER DIAGNOSIS AT THE CROSSROADS

PRECISION MEDICINE DRIVING CHANGE

SEPTEMBER 15-17, 2014 | SHERATON SEATTLE HOTEL | SEATTLE, WA

KEYNOTE SPEAKERS:

Carolyn Compton, M.D., Ph.D.
National Biomarkers Development Alliance and Arizona State University

James M. Olson, M.D., Ph.D.
Fred Hutchinson Cancer Research Center, Seattle Children’s Hospital, Presage Biosciences and Blaze Bioscience

Nathan D. Price, Ph.D.
Institute for Systems Biology

John T. Slattery, Ph.D.
University of Washington School of Medicine

SUNDAY, SEPTEMBER 14

• Short Course: Advances in Patient-Derived Xenograft Models
• Complimentary Onsite Tour: NWBioTrust

TUESDAY, SEPTEMBER 16

• Short Course: Biobanking Operations Management

THURSDAY, SEPTEMBER 18

• Seminar: Informed Consent Content & Process Requirements for Biobanking Studies
ABOUT THE CONFERENCE

Tumor collections provide insight into the great variability of cancer, its progression and its response to treatment. Patient xenografts and cell models (PDX) allow researchers to link and integrate information and determine personal variations in cancer molecular profiles. The recent advancements in high-throughput genomics, proteomics and other -omics platforms allow profiling of large numbers of cancer analytes in a single assay. Thus, knowledge of these altered molecular landscapes offers great promise for developing molecular tests to improve cancer diagnosis and optimize treatment. Cambridge Healthtech Institute’s Inaugural Cancer Diagnosis at the Crossroads: Precision Medicine Driving Change convenes international oncology experts in the fields of tumor biospecimen research, PDX models, molecular diagnostics/prognostics and pharmacogenomics.

PRE-CONFERENCE EVENTS

SUNDAY, SEPTEMBER 14

1:30 pm Short Course Registration

Advances in Patient-Derived Xenograft (PDX) Models*
2:00-5:00

Cancer is a very individualized disease. All agree highly characterized patient-derived tumor tissue xenograft (PDX) models can reveal predictive biomarkers to develop novel targeted therapeutics for personalized treatment. This has resulted in a growing interest in developing collections of PDX models for various cancer research applications in academic and pharma laboratories. This short course focuses on methods for PDX model generation and maintenance, including host mouse strains and organoid cultures.

Instructors to be Announced

*Separate registration required

Onsite Tour of NWBioTrust
(Limited to 50 participants)
6:00-8:00 pm

5:30 pm Shuttle Service to Laboratory Tour
*Complimentary roundtrip shuttle service to and from the Sheraton Seattle Hotel

6:00-7:30 Lab Tour: NWBioTrust Hubs and Spokes System

NWBioTrust (NWBT) is a collaborative project between Fred Hutchinson Cancer Research Center, Institute of Translational Health Sciences, Seattle Cancer Care Alliance, Seattle Children's Hospital and University of Washington Medicine. This innovative hub-and-spokes resource system connects donated biospecimens from consenting individuals with innovative research projects aimed at advancing biomarker discovery and improving prevention, diagnosis and treatment of human disease.

7:30 Board Shuttle and Depart for Hotel

8:00 Close of Day

For updates, please visit healthtech.com/Precision-Medicine-Cancer

Hosted by NWBioTrust

Cover

Current agenda

Sponsor & exhibit

Hotel & travel

Pricing & registration

Register online
### CURRENT AGENDA

**MONDAY, SEPTEMBER 15**

**7:30 am Main Conference Registration and Morning Coffee**

**Plenary Keynote Session: Defining Precision Medicine - It Takes a Village**

**8:30 Welcome and Chairperson’s Opening Remarks**

**8:40 Northwest BioTrust: Consent Specimens, Medical Data and Patient Registry**

John T. Slattery, Ph.D., Vice Dean, Research and Graduate Education, School of Medicine and Professor, Pharmacology and Medicine, University of Washington School of Medicine

The guiding principles and formation of Northwest BioTrust, a system that collects and distributes consented medical data and specimens, and identifies patients interested in participating in clinical research from patients encountering the UW Medicine and Seattle Cancer Care Alliance, will be discussed.

**9:25 The National Biomarkers Development Alliance (NBDA): Advancing Biomarkers Development for Precision Medicine Beginning with Biospecimens**

Carolyn Compton, M.D., Ph.D., CMO, National Biomarkers Development Alliance and Professor, School of Life Sciences, Arizona State University

The development of new robust biomarkers is essential to the realization of the vision of precision medicine. At present, the high costs and failure rates in biomarker development represent a significant roadblock to medical progress. The biomarker development process itself requires re-engineering, beginning with standards for biospecimens, to reduce the massive inefficiencies, fragmentation and failure rates that now characterize the system. This can only be accomplished through broad coordination of effort and consensus, which is the goal of the NBDA.

**10:10 Coffee Break in the Exhibit Hall with Poster Viewing**

**10:30 Integrating the Principles of Preventative and Personalized Medicine to Advance Wellness**

Nathan D. Price, Ph.D., Associate Director, Institute for Systems Biology

Radical, exponentially accelerating technological advancements are enabling individuals to gain greater control over their health than ever before. These endeavors focus on unlocking the power of an expanding array of scientific discoveries and deliver simple, actionable information to each individual to maximize health and minimize disease – even eliminating it at its earliest stages. I will discuss the beginnings of our ISB 100K wellness project aimed at providing a proof-of-concept study for these new approaches to optimizing wellness and minimizing disease.

**11:15 Avatar Models of Rare Pediatric Cancer: An International Resource**

James M. Olson, M.D., Ph.D., Member, Clinical Research Division, Fred Hutchinson Cancer Research Center; Professor, Pediatric Hematology and Oncology, University of Washington; Attending Physician, Seattle Children’s Hospital; Founder, Presage Biosciences and Blaze Bioscience

To enable drug discovery and development tailored to pediatric brain tumors, we created > 30 PDX models (avatars) of pediatric brain cancer. Fred Hutchinson Center’s lab team implanted surgically resected patient cells into mouse brains typically within hours of surgery. The tumors in mice were propagated through multiple passages and extensive genomic profiling was conducted to relate the avatars to the original patient sample. With philanthropic support, these models are available to investigators globally to enable discovery and translational science.

**12:00 pm Close of Session**

**12:15 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own**

**Multiple Paths Lead to Precise Cancer Medicine**

**2:00 Chairperson’s Remarks**

Rajiv Raja, Ph.D., Group Leader, Clinical Assays and Technologies Group, Oncology Biomarker Development, Genentech, Inc.

**2:05 Developing an Institutional Cancer Biorepository for Personalized Medicine**

Angen Liu, M.D., Ph.D., Director, Specimen Accessioning Core, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University

High-quality human biospecimens and associated patient clinical information are key elements of a scientific infrastructure that supports discovery and identification of molecular biomarkers and diagnostic agents. The availability of low-cost whole-genome profiles of individual tumors has opened up new possibilities for personalized medicine to deliver appropriate treatments to individual patients with minimal toxicity. Reliable access to high-quality biospecimens with patient clinical information is crucial. With new genetic and proteomic techniques being developed continuously, the biorepository will greatly advance personalized medicine.

**2:35 Operationalizing Precision Medicine through Biospecimen Management Strategy**

Brenda Yanak, Ph.D., Director, Precision Medicine Leader, Clinical Innovation, Pfizer, Inc. (tentative)

Quality biospecimens are the foundation of precision medicine. This talk will discuss the use of a specimen management framework to operationalize precision medicine.

**3:05 Sponsored Presentation (Opportunity Available)**

**3:35 Refreshment Break in the Exhibit Hall with Poster Viewing**

**4:15 It’s Not Just about Big Data: Big Analytics for Identifying What Works and for Whom in Healthcare**

Iya Khalil, Ph.D., Executive Vice President and Co-Founder, GNS Healthcare

We are living in a transformative time for healthcare driven by the Affordable Care Act and advances in our ability to collect and analyze data on a massive scale. The key to harnessing the power of this data is powerful analytics that rapidly learn from data and identify the best interventions for individual patients in real time.

**4:45 Fluorescently Labeled Chimeric Anti-CEA Antibody Improves Detection and Resection of Gastrointestinal Cancers in Patient-Derived Orthotopic Xenograft (PDX) Nude Mouse Models**

Michael Bouvet, M.D., Professor, Surgery; Director, Endocrine Surgery, Co-Director, GI Cancer Unit, Moores Cancer Center, University of California San Diego

Surgeons face many challenges when attempting curative resection for gastrointestinal cancers. The ability to properly delineate tumor margins for complete resection is of utmost importance in achieving cure and giving the patient the best chance of prolonged survival. Using unique characteristics of the tumor to fluorescently label the tissue can delineate tumor margins from normal surrounding tissue, allowing improved precision of surgical resection. We discuss different methods of fluorescently labeling native tumor tissue as well as the development of fluorescence laparoscopy and potential role for fluorescence-guided surgery in the treatment of gastrointestinal cancers.

**5:15 Novel Technologies Enabling Exploratory Biomarker Analysis in the Clinic**

Rajiv Raja, Ph.D., Group Leader, Clinical Assays and Technologies Group, Oncology Biomarker Development, Genentech, Inc.

Biomarker analysis of tumor biopsies is essential for prognostic and predictive purposes, to identify new drug targets and to understand drug resistance mechanisms. Since the availability of archival patient samples are often extremely limited, we have focused our efforts to develop technologies that increase the sensitivity of molecular analysis of FFPE tissues, allow high degree of multiplexing and minimize the RNA/DNA input requirements for assays, while ensuring robust and high-quality data. Several such approaches will be discussed.

**5:45 Welcome Reception in the Exhibit Hall with Poster Viewing**

**6:30 Close of Day**

---

**Plenary Keynote Session: Defining Precision Medicine - It Takes a Village**

Plenary Keynote Session: Defining Precision Medicine - It Takes a Village

Plenary Keynote Session: Defining Precision Medicine - It Takes a Village

Plenary Keynote Session: Defining Precision Medicine - It Takes a Village

Plenary Keynote Session: Defining Precision Medicine - It Takes a Village
TUESDAY, SEPTEMBER 16

7:30 am Breakfast Presentation (Sponsorship Opportunity Available) or Morning Coffee

8:00 Brainstorming Breakfast Discussion Groups
Grab a cup of coffee and join a discussion group. These are moderated discussions with brainstorming and interactive problem solving, allowing conference participants from diverse backgrounds to exchange ideas and experiences and develop future collaborations around a focused topic.

Genomics’ Role in Individualized Cancer Therapy from Assay Development to Clinical Implementation

9:00 Chairperson’s Remarks
Colin C. Pritchard, M.D., Ph.D., Assistant Professor and Associate Director, Genetics and Solid Tumors Laboratory, Laboratory Medicine, University of Washington

9:05 Bringing Comprehensive Molecular Information into Routine Clinical Care
Josephine N. Harada, Ph.D., MBA, Director, Strategic Alliances, Foundation Medicine, Inc.
Oncology has experienced a recent paradigm shift toward thinking about cancer as a disease of the genome. Next-generation sequencing has furthered our understanding of cancer biology and let us more comprehensively characterize the genomic alterations in an individual patient’s cancer. This profiling approach enables precision medicine in clinical cancer care. Its widespread use could provide more treatment options and enable more rapid accrual to ongoing and planned trials of agents targeting pathways under study, thereby continuing to advance precision medicine.

9:35 Successful Implementation of Precision Medicine in Clinical Cancer Care: The UW Experience
Colin C. Pritchard, M.D., Ph.D., Assistant Professor and Associate Director, Genetics and Solid Tumors Laboratory, Laboratory Medicine, University of Washington
Genomic sequencing technology for diagnostic testing is especially promising for cancer patients, both for hereditary cancer risk assessment and for tumor-based sequencing for precision cancer therapy. Since 2011, the UWMC Genetics lab has offered clinical assays for precision medicine in clinical cancer care that harness genomic next-generation sequencing. We will review considerations related to clinical implementation of this technology and cover gene panels currently in clinical use for cancer patients and their families at UW and SCCA.

10:05 Sponsored Presentation (Opportunity Available)

10:35 Coffee Break in the Exhibit Hall with Poster Viewing

11:15 Development and Validation of a Clinical Trial Patient Stratification Assay that Interrogates 27 Mutation Sites in MAPK Pathway Genes
Ken C. N. Chang, Ph.D., Clinical Assay Development and Outsourcing Lead, Clinical Biomarkers and Diagnostics, Merck & Co., Inc.
A custom-designed Single Nucleotide Primer Extension (SNPE) multiplexing mutation assay was developed and analytically validated as a clinical trial assay for more than 30 specific mutations among three targeted RAS/RAF oncogenes. We used next-generation sequencing to resolve discordant calls between the SNPE mutation assay and Sanger sequencing. We also applied a triplicate rule to reduce potential false positives and false negatives, and proposed special considerations for clinically significant level of mutations including pre-defining a cut-off percentage for each mutant and wild-type.

11:45 Integrating Laboratory and Clinical Informatics for Next-Generation Sequencing Assays
Noah Hoffman, M.D., Ph.D., Assistant Professor, Laboratory Medicine, University of Washington
Next-generation sequencing assays, like human germline and somatic mutations surveys and deep sequencing of mixed bacterial populations, introduce significant complexity to the laboratory and healthcare system. To manage this complexity, our laboratory has invested heavily in staff and infrastructure to support data analysis, interpretation and clinical reporting. We will discuss challenges encountered related to quality control, data management, case signout and reporting into electronic medical records, and describe approaches for addressing these challenges within the UW Medicine healthcare system.

12:15 pm Close of Session

12:30 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

Deciphering Cancer’s Complexity Takes Multidisciplinary Integration

2:00 Chairperson’s Remarks
Sui Huang, M.D., Ph.D., Professor, Institute of Systems Biology

2:05 Glycan “Node” Analysis for Detecting and Monitoring Cancer
Chad R. Borges, Ph.D., Assistant Professor, Chemistry and Biochemistry, The Biodesign Institute – Center for Personalized Diagnostics, Arizona State University
Cancer biologists have known for many years that tumor cells display abnormal glycan structures. Dr. Borges has developed a technique to quantify glycan structural characteristics in blood serum that provides a completely new angle by which to leverage glycans as markers to identify and classify cancer. Results from studies of lung cancer and several other different types of cancer will be presented.

2:35 Integrative Genomic Analysis of Gastric Cancer
Kai Wang, Ph.D., Principal Scientist, Oncology Research Unit, Pfizer, Inc.
Gastric cancer is a heterogeneous disease with diverse molecular and histological subtypes. We performed comprehensive genomic profiling in a large cohort of gastric cancers for integrative genomic analysis. Our data revealed subtype-specific genetic, epigenetic perturbations and unique mutational signatures. We identified previously known (TP53, ARID1A and CDH1) and new significantly mutated driver genes. These findings illustrate a multidimensional and comprehensive genomic landscape that highlights the molecular complexity of gastric cancer and provides a roadmap to facilitate genome-guided personalized therapy.

3:05 Sponsored Presentation (Opportunity Available)

3:35 Refreshment Break in the Exhibit Hall with Poster Viewing

4:00 An Inducible, Isogenic Cancer Cell Line System for Targeting the State of Mismatch Repair Deficiency
Julie Bailis, Ph.D., Senior Scientist, Oncology Research, Amgen, Inc.

4:30 Complex Cell Response to Therapy as Basis for Therapy Resistance in Cancer Cells: “What Does Not Kill Me Makes Me Stronger”
Sui Huang, M.D., Ph.D., Professor, Institute of Systems Biology
Current cancer research operates with the tacit assumption that our understanding of cancer cell behavior is established, and all that is needed is to identify new molecular targets and target them. But as single-cell analysis and new theories reveal, beyond this paradigm exists the realm of complex adaptive systems dynamics, enduring cancer cells with the unfathomable ability to act collectively as a population to mount an evasive response to treatment, allowing non-killed cells to become even more malignant.

3:00 An Inducible, Isogenic Cancer Cell Line System for Targeting the State of Mismatch Repair Deficiency
Julie Bailis, Ph.D., Senior Scientist, Oncology Research, Amgen, Inc.

4:30 Complex Cell Response to Therapy as Basis for Therapy Resistance in Cancer Cells: “What Does Not Kill Me Makes Me Stronger”
Sui Huang, M.D., Ph.D., Professor, Institute of Systems Biology
Current cancer research operates with the tacit assumption that our understanding of cancer cell behavior is established, and all that is needed is to identify new molecular targets and target them. But as single-cell analysis and new theories reveal, beyond this paradigm exists the realm of complex adaptive systems dynamics, enduring cancer cells with the unfathomable ability to act collectively as a population to mount an evasive response to treatment, allowing non-killed cells to become even more malignant.
CURRENT AGENDA

5:00 Molecular Alterations and Biomarkers in Colorectal Cancer
William M. Grady, M.D., Director, Translational Research and Rodger C. Haggitt Professor, Gastroenterology, School of Medicine, University of Washington; Medical Director, GI Cancer Prevention Program, Seattle Cancer Care Alliance; Member, Clinical Research Division, Fred Hutchinson Cancer Research Center

The promise of precision medicine is a clinical reality. Our advanced understanding of the molecular genetics of colorectal cancer is helping us develop biomarkers that are being used as early detection markers, prognostic markers and markers for predicting treatment responses. We will discuss our current understanding of the molecular pathogenesis of colorectal cancer and how these alterations relate to emerging biomarkers for early detection and risk stratification (diagnostic markers), prognosis (prognostic markers) and the prediction of treatment responses (predictive markers).

5:30 Close of Day

5:15-5:45 Dinner Short Course Registration

5:45-9:00 DINNER SHORT COURSE: WHAT IT TAKES TO BE A BIOBANKING OPERATIONS MANAGER: FROM PATIENT INTERACTION TO FREEZER INSPECTION*

Dinner Short Course Description
This course provides the comprehensive background information, requirements and guidelines necessary to successfully run biobanks while also serving clients. To translate research needs to a high-functioning lab program that produces high-quality biomaterial and data deliverables, detailed upfront planning, efficient processes, cutting-edge science and technology plus an understanding of program management are critical. Such elements affecting strategic and day-to-day responsibilities, as well as fundamentals like staying within time, cost, scope and quality constraints while meeting customer needs; maintaining proper documentation, from Standard Operating Procedures to training records, in a controlled environment; and contingency operations for freezer malfunction will be presented. The course will benefit not only biorepository operations managers, but also nurses, administrators of sample collection and storage entities and even research scientists who will better understand how biobanker practices align with and support their own goals.

Learning Objectives
• Share effective program and project launches
• Describe program governance
• Explain the establishment of a strong communication plan
• Discuss quality assurance and control
• Describe the process of controlling and mitigating risk
• Provide tips for managing stakeholder expectations
• Explain the importance of properly closing a project
• Provide guidelines for formatting and streamlining an SOP
• Discuss the contents to include in different SOP sections
• Describe training records and how to best maintain them
• Share the factors and circumstances a site auditor will want to see
• Describe the process of version controlling both training records and SOPs
• Explain disaster management and the need for backup SOPs

Who Should Attend
• Biobank and Biorepository Operations Managers
• Sample Collection and Storage Administrators
• Nurses
• Research Scientists

Instructors
Stephanie Frahm, Senior Project Manager and Technology Developer, RUCDR Infinite Biologics, Rutgers University
Colleen M. Mitchell, Joint Biorepository Operations Manager, Indiana University
Genetics Biobank and Indiana Biobank

Course Length and Time
3.25 hours 5:45 – 9:00 p.m.

Course Date
September 16, 2014

FEE: $699 Commercial/ $399 Academic, Government, Hospital-Affiliated

ACCREDITATION
Barnett International is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Participants will receive 3.25 hours (0.325 CEUs) of continuing education credit for full participation, including the completion of a pre-test, post-test, and program evaluation. Barnett International will email ACPE statements within three weeks of program completion.

ACPE#: 0778-0000-14-091-L01-P
Released: 9/14.

*Separate registration required
Case Studies: Biobanker/Biouser Partnerships
(Sponsorship Opportunities Available)

Biomedical researchers and drug developers require accessible, high-quality biospecimens that allow them to extract reliable and useful data. Oncology experts, for instance, use patient-derived tumor collections to connect datasets, pinpoint and assess variants within cancer patients post-diagnosis and zero in on the data that matter when tailoring therapies. Early, strategic collaborations with the biobanks that house specimens can be mutually beneficial, maximizing the financial and technological investments of the operation managers who collect, store, annotate and distribute the biological samples ("biobankers") and supporting the research goals of the scientists who need those samples ("biouers") — all to fulfill the promise of personalized medicine.

This session brings together both partners in a co-presentation to illustrate their collaboration and elaborate on the following issues:

- How does the partnership work?
- What are the bottlenecks?
- What does each bring to the table?
- What are the needs?
- Ultimately, what are the scientific results?

1:30 Chairperson’s Remarks

1:35 Case Study #1: A Clinical Trial of Cellular Adoptive Immunotherapy in Patients with Melanoma: Integrating Biospecimen Procurement and Therapeutics
Sylvia M. Lee, M.D., Research Associate, Immunology Program, Clinical Research Division, Fred Hutchinson Cancer Research Center and Medical Oncologist, Seattle Cancer Care Alliance

Infusion of tumor-infiltrating lymphocytes after combination chemotherapy may provide benefit in patients afflicted with melanoma. This presentation will highlight successful implementation of a cellular adoptive immunotherapy clinical trial integrating biospecimen procurement and laboratory science.

2:20 Case Study #2 (Sponsorship Opportunity Available)

3:05 Case Study #3 (Sponsorship Opportunity Available)

3:50 Case Study #4 (Sponsorship Opportunity Available)

4:35 Closing Remarks

4:45 Close of Conference

---

**Post-Conference Event**

**THURSDAY, SEPTEMBER 18**

**Informed Consent Content and Process Requirements in Biobanking Studies**

*8:30 am-5:00 pm*

This course presents the elements of the informed consent document and the components of the process, specifically as they relate to biobanking studies.

Instructor: Elizabeth Ronk Nelson, MPH, Barnett International

Participants will receive 7 hours (0.7 CEUs) from Accreditation Council for Pharmacy Education for full participation. For further information please visit barnettinternational.com

*Separate registration required*
**HOTEL & TRAVEL INFORMATION**

**Conference Hotel:**
Sheraton Seattle Hotel  
1400 5th Avenue  
Seattle, WA 98101  
Telephone: 206-621-9000

**Discounted Room Rate:** $185 s/d  
**Discounted Cut-off Date:** August 18, 2014

**Why Stay at the Sheraton Seattle?**
The Sheraton Seattle is a vibrant, modern slice of Seattle. Located in the heart of downtown, the Sheraton Seattle is just steps away from dining, shopping, sites and all the best Seattle has to offer. Meeting attendees receive complimentary wireless internet in their guest room, and access to the hotel’s state-of-the-art fitness center. Combine these with a modern business center and several restaurants on premises, and the Sheraton Seattle becomes the clear and easy choice for the conference attendee.

We understand that you have many choices when making your travel arrangements. Please understand that reserving your room in the CHI room block allows you to take full advantage of the conference sessions, events and networking opportunities, and ensures that our staff will be available to help should you have any issues with your accommodations.

**Flight Discounts:**
Special discounts have been established with American Airlines. Please use one of the following methods:
- Call 1-800-433-1790 and use Conference code 8594BS
- Go to www.aa.com/group and enter Conference code 8594BS in promotion discount box
- Contact our designated travel agent, Rona Meizler at 617-559-3735 or Rona.Meizler@protravelinc.com

**Car Rental Discounts:**
Special discount rentals have been established with Hertz for this conference. Call Hertz directly at 800-654-3131 and reference our Hertz Convention Number (CV) 04KL0005

**Held in Conjunction With**

6th International Leaders in Biobanking Congress 2014

Today, biospecimen collections are used by multiple research groups for varying research aims, from basic research through clinical trials. A well-managed biobank is a critical prerequisite for high-quality biological research. The proper collection, processing, storage and tracking of biospecimens are critical components allowing researchers to better link molecular and clinical information. Thus, by necessity, biobanking is both a science and a business. Cambridge Healthtech Institute’s Sixth Annual Leaders in Biobanking Congress: Maximizing Your Investment in Biospecimens addresses both the business and science of biobanking, bringing together biomedical and biopharmaceutical researchers, regulators, biorepository managers and practitioners to investigate the best strategies for effective use of biospecimens within today’s cutting-edge research. To learn more, visit: healthtech.com/biobanking.
SPONSOR & EXHIBIT OPPORTUNITIES

CHI offers comprehensive sponsorship packages which include presentation opportunities, exhibit space, branding and networking with specific prospects. Sponsorship allows you to achieve your objectives before, during, and long after the event. Any sponsorship can be customized to meet your company’s needs and budget. Signing on early will allow you to maximize exposure to qualified decision makers.

Podium Presentations – Within Main Agenda!
Showcase your products/solutions to a guaranteed, targeted audience. Package includes a 15 or 30-minute podium presentation within the scientific agenda, exhibit space, on-site branding, access to cooperative marketing efforts by CHI, and more.

Breakfast & Luncheon Podium Presentations
Opportunity includes a 30-minute podium presentation. Boxed lunches are delivered into the main session room, which guarantees audience attendance and participation. A limited number of presentations are available for sponsorship and they will sell out quickly. Sign on early to secure your talk!

Invitation-Only VIP Dinner/Hospitality Suite
Sponsors will select their top prospects from the conference pre-registration list for an evening of networking at the hotel or at a choice local venue. CHI will extend invitations and deliver prospects, helping you to make the most out of this invaluable opportunity. Evening will be customized according to sponsor’s objectives (i.e. purely social, focus group, reception style, plated dinner with specific conversation focus).

Exhibit
Exhibitors will enjoy facilitated networking opportunities with qualified delegates. Speak face-to-face with prospective clients and showcase your latest product, service, or solution.

*Additional branding & promotional opportunities are available!

For sponsorship and exhibit information, please contact:
Carolyn Benton
Business Development Manager
cbenton@healthtech.com
781-972-5412
**Pricing and Registration Information**

**SHORT COURSES**

<table>
<thead>
<tr>
<th></th>
<th>Commercial</th>
<th>Academic, Government, Hospital-affiliated</th>
</tr>
</thead>
<tbody>
<tr>
<td>One short course</td>
<td>$699</td>
<td>$399</td>
</tr>
<tr>
<td>Two short courses</td>
<td>$999</td>
<td>$699</td>
</tr>
</tbody>
</table>

**CONFERENCE PRICING**

**STANDARD PACKAGE** *(includes access to Cancer Diagnosis at the Crossroads: Precision Medicine Driving Change PLUS onsite tour of NWBiOTrust, excludes short courses)*

<table>
<thead>
<tr>
<th>Registration Period</th>
<th>Commercial</th>
<th>Academic, Government, Hospital-affiliated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Special Early Discount until May 30, 2014</td>
<td>$1899</td>
<td>$899</td>
</tr>
<tr>
<td>Early Discount until June 27, 2014</td>
<td>$1999</td>
<td>$999</td>
</tr>
<tr>
<td>Advanced Discount until August 15, 2014</td>
<td>$2099</td>
<td>$1069</td>
</tr>
<tr>
<td>Registrations after August 15 and on-site</td>
<td>$2249</td>
<td>$1129</td>
</tr>
</tbody>
</table>

- Yes, I will attend the Onsite Tour. *(Included in Registration. Tour limited to first 50 participants.)*

**POST-CONFERENCE EVENT** *(includes access to Informed Consent Content & Process Requirements for Biobanking Studies ONLY)*

<table>
<thead>
<tr>
<th>Registration Period</th>
<th>Commercial</th>
<th>Academic, Government, Hospital-affiliated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Registration Discount until August 15, 2014</td>
<td>$800</td>
<td>$700</td>
</tr>
<tr>
<td>Registrations after August 15, 2014, and on-site</td>
<td>$1000</td>
<td>$800</td>
</tr>
</tbody>
</table>

**CONFERENCE DISCOUNTS**

- Poster Submission - Discount ($50 Off): Poster abstracts are due by August 15, 2014. Once your registration has been fully processed, we will send an email containing a unique link allowing you to submit your poster abstract. If you do not receive your link within 5 business days, please contact Jring@healthtech.com. *CHI reserves the right to publish your poster title and abstract in various marketing materials and products.*

**REGISTER 3 - 4th IS FREE:** Individuals must register for the same conference or conference combination and submit completed registration form together for discount to apply.

- **Alumni Discount:** Cambridge Healthtech Institute (CHI) appreciates your past participation at any CHI conference. As a result of the great loyalty you have shown us, we are pleased to extend the exclusive opportunity to save an additional 20% off the registration rate.

- **Group Discounts:** Discounts are available for multiple attendees from the same organization. For more information on group rates contact David Cunningham at +1-781-972-5472

**ADDITIONAL REGISTRATION DETAILS**

Each registration includes all conference sessions, posters and exhibits, food functions, and access to the conference proceedings link.

Handicapped Equal Access: In accordance with the ADA, Cambridge Healthtech Institute is pleased to arrange special accommodations for attendees with special needs. All requests for such assistance must be submitted in writing to CHI at least 30 days prior to the start of the meeting.

To view our Substitutions/Cancellations Policy, go to http://www.healthtech.com/regdetails

Video and or audio recording of any kind is prohibited onsite at all CHI events.

If you are unable to attend but would like to purchase the Cancer Diagnosis at the Crossroads: Precision Medicine Driving Change CD for $350 (plus shipping), please visit healthtech.com/biobanking. Massachusetts delivery will include sales tax.

How to Register: healthtech.com/precision-medicine-cancer

reg@healthtech.com
P: 781.972.5400 or Toll-free in the U.S. 888.999.6288
Please use key code CGN F when registering